866-997-4948(US-Canada Toll Free)

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 70 Pages

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2017

Summary

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis.

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 2, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Leukemias, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Breast Cancer, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Papillomavirus (HPV) Associated Cancer, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Small-Cell Lung Cancer.

The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2017, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview 6
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development 22
Boehringer Ingelheim GmbH 22
Cyclacel Pharmaceuticals Inc 22
Marina Biotech Inc 23
Onconova Therapeutics Inc 23
Takeda Pharmaceutical Co Ltd 24
Trovagene Inc 24
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles 26
CYC-140 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LS-008 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
M-400 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PCM-075 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
rigosertib sodium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit PLK1 for Oncology - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Inhibit PLK1 for Oncology - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecules to Inhibit PLK1 for Squamous Cell Carcinoma - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
volasertib trihydrochloride - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products 55
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products 58
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones 59
Featured News & Press Releases 59
Nov 01, 2017: Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting 59
Oct 18, 2017: Trovagenes PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells 59
Oct 10, 2017: Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 60
Oct 09, 2017: FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) 60
Oct 04, 2017: Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City 61
Aug 21, 2017: Trovagenes PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines 61
Aug 16, 2017: Trovagenes PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy 62
Jul 27, 2017: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia 62
Jul 25, 2017: Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric RASopathies 63
Jul 25, 2017: Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075s potential as safe and effective treatment for solid tumor and hematological malignancies 64
Jul 06, 2017: Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 64
Jun 29, 2017: Trovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial 65
Jun 27, 2017: Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia 65
Jun 26, 2017: Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid 66
Jun 26, 2017: Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indications, H2 2017 9
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by Boehringer Ingelheim GmbH, H2 2017 22
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 23
Pipeline by Marina Biotech Inc, H2 2017 23
Pipeline by Onconova Therapeutics Inc, H2 2017 24
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 24
Pipeline by Trovagene Inc, H2 2017 25
Dormant Products, H2 2017 55
Dormant Products, H2 2017 (Contd..1), H2 2017 56
Dormant Products, H2 2017 (Contd..2), H2 2017 57
Discontinued Products, H2 2017 58

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Routes of Administration, H2 2017 18
Number of Products by Stage and Routes of Administration, H2 2017 18
Number of Products by Molecule Types, H2 2017 20
Number of Products by Stage and Molecule Types, H2 2017 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *